阿司匹林预防恶性肿瘤患者静脉血栓形成的临床疗效分析

目的观察阿司匹林肠溶片预防恶性肿瘤患者深静脉血栓形成的临床疗效。方法 46例恶性肿瘤患者随机分为实验组和对照组,每组各23例。实验组在化疗结束后行局部放疗的同时给予口服肠溶阿司匹林和胃黏膜保护剂麦滋林-S颗粒,对照组给予安慰剂治疗。通过检测血清中D-二聚体和纤维蛋白原的含量以及彩色多普勒血流显像判断患者静脉血栓形成情况,同时观察患者不良反应的发生情况。结果实验组静脉血栓的发生率为4.35%,显著低于对照组(21.74%),差异有统计学意义(P<0.05),且无显著过敏、血小板减少以及出血倾向等不良反应发生。结论口服阿司匹林肠溶片可有效预防恶性肿瘤患者静脉血栓的发生。

The Clinical Effects of Aspirin on the Formation of Phlebothrombosis in Malignant Tumor Patients

Objective To observe the clinical effects of Aspirin on the phlebothrombosis formation in patients with malignant tumor.Methods 46 malignant tumor patients were selected and randomly divided into experimental group and control group,23 patients in each group.Patients in the experimental group were given enteric-coated aspirin orally as well as Marzulene-S granules during the local radiotherapy after chemotherapy,while patients in the control group were given placebo.The incidence of phlebothrombosis was evaluated by detecting the content of d-dimer and fibrinogen in the serum and colour-code Doppler ultrasonography.The adverse effects were also observed in the meantime.Results The incidence rate of phlebothrombosis in the experimental group was 4.35%,significantly lower than the control group(21.74%)(P<0.05).In addition,no significant adverse effects such as allergy,thrombocytopenia and hemorrhagic tendency were observed in experimental group.Conclusion Aspirin was able to effectively prevent the incidence of phlebothrombosis in malignant tumor patients.